WASHINGTON (AP) - Food and Drug Administration scientists are questioning whether study results are reliable enough to warrant approval for a new cancer drug from Johnson & Johnson.
J&J's Ortho Biotech unit has asked the FDA to approve the injectable drug Yondelis for women with recurring ovarian cancer. It would be used with J&J's cancer drug Doxil.
But regulators are concerned the company's results may not be reliable because of a large number of inconsistencies.
The company's data use imaging scans designed to show a halt in progression of the cancer. But radiology experts hired by J&J disagreed on what the images showed 39 percent of the time.
The FDA's outside cancer experts will weigh in on the results Wednesday.
Web Search powered by YAHOO!
|
LifestylesLifestyles
FDA questions data for J&J ovarian cancer drug
WASHINGTON (AP) - Food and Drug Administration scientists are questioning whether study results are reliable enough to warrant approval for a new cancer drug from Johnson & Johnson.
By:
|
WNCT
Published: July 13, 2009
Published: July 13, 2009
Email
Facebook
Google
Twitter
Favorites
MoreAdvertisement
View More:
Cancer,
Data Use Imaging,
Doxil,
Food And Drug Administration,
Health_Medical_Pharma,
J&J'S Cancer,
Johnson & Johnson,
Ovarian Cancer,
Washington,
Yondelis
Not what you're looking for? Try our quick search:
Reader Comments
*Facebook Account Required to Comment. If you are not already logged into Facebook, please click the comment button to do so.Deal of the Day
Advertisement
Interactive Radar
Advertisement
Featured Blogger
Reel Reviews
Updated: 02/10/2012
Nine On Your Side's Phillip Sayblack shares his take on the latest movie and dvd releases.
More Posts by Reel Reviews
Hot Topics on WNCT.com
Advertisement
Advertisement